dr-chris-dvorak-md-106-1440x784-2x
Christopher Dvorak

Christopher Dvorak

MD

Pediatric hematologist-oncologist
Bone marrow transplant specialist
Chief, Pediatric Allergy, Immunology and Bone Marrow Transplant Division
Sherlock Holmes enthusiast

Contact me

Contact me

Dr. Christopher Dvorak is a specialist in stem cell transplantation for children with immunodeficiencies, blood disorders and cancer. He is chief of the UCSF Pediatric Allergy, Immunology and Bone Marrow Transplantation (BMT) Division and director of the Pediatric Cellular Therapy Laboratory.

In his research, Dvorak studies ways to lower the incidence of relapse in patients who have stem cell transplants for childhood leukemia. He also investigates how to minimize BMT complications and how to improve outcomes after stem cell transplants for severe combined immunodeficiencies (genetic disorders in which infants lack normal immune function), often called SCID.

Dvorak earned his medical degree at Vanderbilt University School of Medicine. He completed a residency in pediatrics as well as a fellowship in pediatric hematology, oncology and BMT at Stanford Medicine. Before joining UCSF in 2007, he was a clinical instructor for Stanford Medicine in the pediatric stem cell transplantation division.

Dvorak is a national co-leader of the Primary Immune Deficiency Treatment Consortium, and he leads the Cancer Control and Supportive Care Committee for the Children's Oncology Group.

  • Board Certifications

    American Board of Pediatrics, Pediatric Hematology-Oncology

  • Fellowships

    Lucile Salter Packard Childrens Hospital -Stanford, Ped. Hema/Oncology

  • Residencies

    Stanford University Medical Center-GME, Pediatrics

  • Internship

    Stanford University Medical Center-GME, Pediatrics

  • Degree

    MD, Vanderbilt University

Bone marrow transplant is a complex procedure with significant risks. My passion is to make it so safe that anyone could have a successful transplant.

Where I see patients (2)

    Selected research

    See all research
    Decorative Caduceus

    A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

    The cumulative incidence of Grade III-IV acute GVHD at Day 100 will be summarized by incidence curves. GVHD evaluations will be performed using standard criteria.37 Patients with graft rejection will be censored.

    Recruiting

    More about this study
    Decorative Caduceus

    EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

    Patients will be monitored for adverse events related to the infusion of EBV CTLs

    Recruiting

    More about this study
    Decorative Caduceus

    A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immun...

    Engraftment is defined as the first of three days of absolute neutrophil count >500,000/µL and the first of seven days of platelets >20,000/µL in the absence of transfusional support.

    Recruiting

    More about this study
    See all clinical trials

    My work

    Precision treatment helps children with blood cancer

    Dr. Dvorak developed a cutting-edge therapy that minimizes the amount of chemotherapy kids like Astrid King need to beat blood cancer.

    Read Astrid's story

    Contact me

    Fetal surgery firsts

    The first open fetal surgery in the world was performed at UCSF in the early 1980s.

    Share